SymGene79™ NGS Cancer Panel

The SymGene79™ cancer panel includes carefully selected oncogenes and tumor suppressor genes with compelling clinical and biological evidences as biomarkers to predict responses to targeted therapies.

• Most of which have received FDA approval as standard treatment for certain tumor types.
• Genetic profiling of these genes is useful for assessing prognosis and guiding treatment of individuals with advanced cancer who have exhausted standard treatment options.
• The panel can also be used to help determine clinical trial eligibility for patients with alterations in genes not amenable to current FDA-Approved targeted therapies.

Test Description

• Genes have been selected based on the most recent literature review.
• Designed for tumor profiling of primary or metastatic major solid tumor types.
• Assessing the entire coding exons of each gene for substitutions, insertions and deletions less than 50 bp, copy number variants (gene amplifications or homozygous loss).

Process & Reporting

• • FFPE blocks are preferred but cytology smears are acceptable.
  • All information on the report is individually evaluated by a geneticist and molecular pathologist.
  • Genomic data is correlated with the morphology by our expert pathologists before reporting.

Interested in ordering SymGene? Please contact us here and we will get back to you shortly.